Target Versus Modified-Standard Fortification of Human Milk and Growth of Very Low Birth Weight Infants: A Double-Blind Randomized Trial.

```mdx

TL;DR: In a double-blind randomized trial of very low birth weight (VLBW) infants, individualized high-protein "target" fortification of human milk did not improve weight gain or 24-month neurodevelopmental scores compared with an optimized high-protein standard fortifier. Evidence tier: single RCT, n = 106 randomized (54 analyzed in the MSF arm, 52 in the TFO arm), single center.

What the study found

Human milk composition varies considerably, both between mothers and within the same mother over time, and standard fortifiers may not supply enough protein for every very low birth weight infant. This gap is the basis for "target" or individualized fortification, which adjusts the nutrient content of milk to each infant's needs. The approach is widely promoted on the assumption that closer matching of protein intake will translate into better growth and, later, better neurodevelopment.

This trial tested that assumption directly. Infants born between 24 and 31 weeks of gestation, receiving 100 mL/kg/day of standard fortified human milk, were randomized in a double-blind design to either modified-standard fortification (MSF), in which protein and medium-chain triglycerides were added to the standard fortifier, or high-protein target fortification (TFO). Both groups received feeding until 36 weeks postmenstrual age (PMA). The comparator was therefore not standard fortification alone but an optimized high-protein standard regimen, which is a stricter test of whether individualization adds anything.

The primary outcome was weight-gain velocity from randomization to 36 weeks PMA. The trial was powered to detect a difference of 0.666 standard deviations. Weight-gain velocity did not differ between groups. The mean difference (MSF minus TFO) was -0.18 g/kg/day (95% CI -1.02 to +0.67; p = 0.68). Anthropometric measures, z-scores, skinfold thickness, and cranial widths at 36 weeks PMA were also similar between groups, as were Bayley-III scores at 24 months.

The authors' conclusion is that, compared with optimized high-protein standard fortification, high-protein target fortification did not improve growth or neurodevelopmental outcomes. Because the study was single-center and enrolled 106 infants, it has limited power for small differences or for rarer outcomes, and the confidence intervals, while narrow around zero, do not exclude modest effects in either direction. Neither arm was compared against unfortified or lower-protein feeding, so the trial speaks to the marginal value of individualization over an already protein-optimized standard, not to fortification as a whole.

What this means for you

Optimized standard fortification performed as well as individualized fortification on the outcomes measured here. For neonatal clinicians and parents evaluating feeding options, this suggests that the added complexity of target fortification is not automatically justified by growth or 24-month neurodevelopmental data from this trial.

Protein intake matters, but the form of optimization may matter less than assumed. Both arms received high-protein regimens. The trial does not show that protein supplementation is unnecessary for VLBW infants, only that individualizing it beyond an optimized standard did not change these outcomes.

The evidence base is still developing. A single trial with 106 randomized infants is informative but not conclusive. Replication across centers and longer follow-up would strengthen confidence.

Discuss feeding decisions with the neonatal care team. Fortification strategy should be tailored to each infant's clinical situation, and nothing in this study changes the individualized monitoring that NICU teams provide.

This study concerns infant nutrition in a clinical setting. It is not evidence about any supplement or adult habit, and no product-level recommendation follows from it.

Study details

Item	Detail
Study type	Single-center, double-blind randomized controlled trial
Population	Very low birth weight infants, 24+0 to 31+6 weeks gestation
Sample size	106 randomized; MSF n = 54, TFO n = 52
Intervention	High-protein target fortification (TFO)
Comparator	Modified-standard fortification (MSF), optimized high-protein standard regimen
Duration	Until 36 weeks postmenstrual age
Primary outcome	Weight-gain velocity, randomization to 36 weeks PMA
Key result	MSF minus TFO: -0.18 g/kg/day (95% CI -1.02 to +0.67; p = 0.68)
Secondary outcomes	Anthropometry, z-scores, skinfold thickness, cranial widths at 36 weeks PMA; Bayley-III at 24 months (no differences)
Journal	Nutrients
PubMed ID	42884692

Sources

1. Target Versus Modified-Standard Fortification of Human Milk and Growth of Very Low Birth Weight Infants: A Double-Blind Randomized Trial. *Nutrients*. PubMed. https://pubmed.ncbi.nlm.nih.gov/42884692/

```

ProtocolEngine provides general health information based on published research. This is not medical advice. Consult a healthcare professional before starting any supplement or health protocol.